A longitudinal analysis of 67 patients with cHER2 detected during follow-ups found that those whose cHER2 status changed from high-risk at baseline to low-risk at first follow-up exhibited a significantly improved survival compared to those whose cHER2 remained high-risk (median PFS: 11.7 weeks vs. Similar results were obtained after adjusting covariates. In comparison, anti-HER2 targeted therapy did not affect PFS among those with low-risk cHER2 (HR 0.70, 95% CI 0.36-1.38, P = 0.306). Among the patients with high-risk cHER2, those who received anti-HER2 targeted therapies had improved PFS compared with those who did not (HR 0.30, 95% CI 0.10-0.92, P = 0.035). Association between cHER2 status and progression-free survival (PFS) was analyzed by univariate and multivariate Cox models and survival differences were compared by Kaplan-Meier method.ResultsCompared to the patients with low-risk cHER2 (cHER2+ + ≥ 2) had shorter survival time and an increased risk for disease progression (hazard ratio 2.16, 95% confidence interval 1.20-3.88, P = 0.010). It remains largely underexplored whether patients with tHER2-/cHER2+ can benefit from anti-HER2 targeted therapies.MethodscHER2 status was determined in 105 advanced-stage patients with tHER2- breast tumors.
PurposeDiscordance between HER2 expression in tumor tissue (tHER2) and HER2 status on circulating tumor cells (cHER2) has been reported.
0 kommentar(er)
